Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06101147
Other study ID # BSMMU/2023/11021
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 21, 2023
Est. completion date June 30, 2024

Study information

Verified date October 2023
Source Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Contact Nilufar Yasmin, MD
Phone 01935444975
Email nilufaryasmin975@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized, double blind, placebo-controlled clinical trial is to learn about, the effect of low dose vitamin D supplementation compares with placebo-controlled group on testosterone level in women with polycystic ovary syndrome. Half of Participants will receive vitamin D and metformin while other half placebo and metformin.


Description:

PCOS poses a significant challenge to women's health and quality of life. PCOS is a common heterogenous endocrine disorder in reproductive-aged women. PCOS is characterized by the presence of polycystic ovaries, menstrual dysfunction, infertility and biochemical (elevated androgens) and clinical (hirsutism and/or acne) hyperandrogenism. Hyperandrogenism and insulin resistance exacerbate one another in the development of PCOS, Research has suggested a potential link between Vitamin D deficiency and the prevalence and severity of PCOS. There is also evidence that Vitamin D has a direct effect on the ovaries and adrenal glands, which are the primary sites of androgen production in women. Vitamin D has been found to inhibit the synthesis of androgens in these glands, suggesting that it could potentially be used to manage hyperandrogenism in women with PCOS. Furthermore, studies have shown that Vitamin D supplementation can reduce insulin resistance in women with PCOS, which can subsequently lead to a decrease in the overproduction of androgens. may improves menstrual irregularities. In human ovarian tissue, vitamin D stimulation of oestrogen and progesterone production and lack of effect on testosterone production may be explained by the expression of the aromatase gene and augmentation of aromatase activity by vitamin D. Serum 25OH-D level has been shown to be negatively correlated with serum androgen levels DHEAS, testosterone and hirsutism. Assumption that vitamin D supplementation may also have a positive impact on serum testosterone levels. Metformin is prescribed for reducing IR in PCOS women. This is a double-blind, randomized placebo-controlled trial in PCOS women who are receiving Metformin therapy. The intervention group will receive Vitamin D Cholecalciferol (D3) 1000 I.U daily for 8 weeks, with the Metformin as prescribed by the physician whereas control group will receive placebo with Metformin during the study period. We will compare change of Total Testosterone, Vitamin D level, Fasting blood glucose, Hirsutism, Menstrual regularities and BMI, at the time of recruitment with after 8 weeks intervention in both the intervention and placebo controlled groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date June 30, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Diagnosed case of PCOS Age 18 years to 45 years Exclusion Criteria: - Pregnancy, lactating women Diagnosed case of diabetes mellitus, liver disease, heart disease, kidney stones and disease, Tuberculosis, hyperparathyroidism Patients receiving vitamin D, calcium supplementation within the last two months Known hypersensitivity to Vitamin D Patients unwilling to participate or unwilling to give written consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vitamin D3
These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
Placebo Oral Tablet
These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group

Locations

Country Name City State
Bangladesh BSMMU Dhaka

Sponsors (1)

Lead Sponsor Collaborator
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Testosterone The estimated testosterone level, is 15-46 ng/dL for a reproductive aged normal menstrual cycles woman . The results demonstrate that there is a diurnal rhythm of testosterone secretion during in girls, with the highest levels in the morning 6 am-10 am .Biochemical hyperandrogenism (TT >46 ng/dl) 1 year
Secondary Fasting blood glucose Impaired fasting glucose (IFG) when FBG is between 5.6-6.9 mmol/L 1 year
Secondary Menstrual regularity Polymenorrheic (<21 days),
Eumenorrheic (21 - 35 days),
Oligomenorrheic (36 days - 3 months) and
Amenorrheic (>3 months)
1 year
Secondary Hirsutism mFG score of =6 1 year
Secondary Vitamin D A blood level of less than 20 ng/ml is considered deficiency, insufficiency is 21- 29 ng/ml, and sufficiency is 30 ng/ml or higher. 1 Year
Secondary BMI Status BMI Underweight 15-19.9 Normal weight 20-24.9 Overweight 25-29.9 Class I Obesity 30-34.9 Class II Obesity 35-39.9 Class III Obesity = 40 1 Year
See also
  Status Clinical Trial Phase
Completed NCT02037672 - PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Phase 4
Completed NCT01833949 - Unilateral Laparoscopic Diathermy Adjusted to Ovarian Volume N/A
Completed NCT03608813 - Myo-inositol, D-chiro-inositol and Glucomannan in PCOS
Not yet recruiting NCT05298657 - The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment
Completed NCT05951309 - Myoinositol Treatment and Asprosin Levels in PCOS N/A
Enrolling by invitation NCT04485403 - The Effect of Ibuprofen on Women With PCOS. Phase 2
Not yet recruiting NCT03978013 - Pomegranate Juice Effect on Oxidative Stress in Infertile Women During IVF Treatment N/A
Recruiting NCT03767569 - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Phase 3
Completed NCT05843955 - Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
Recruiting NCT05971849 - Dampening the Reproductive Axis With Continuous Kisspeptin Phase 1
Recruiting NCT04597099 - Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion Early Phase 1
Active, not recruiting NCT05206448 - Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation Phase 4
Recruiting NCT02358421 - Prediction of High Ovarian Response After Assisted Reproductive Techniques N/A
Completed NCT04113889 - Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome Phase 2
Completed NCT04562883 - Single vs. Group CAPA-IVM Culture of Cumulus-oocyte Complexes N/A
Recruiting NCT03264638 - A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS Phase 2
Completed NCT00594217 - Determining How Quickly Progesterone Slows LH Pulse Frequency Phase 1
Recruiting NCT02024984 - Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial Phase 1
Completed NCT01709942 - Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) Phase 3
Completed NCT01911468 - Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Phase 4